Skip to main content
. 2014 Feb 20;2(3):479–487. doi: 10.3892/mco.2014.264

Figure 3.

Figure 3.

Kaplan-Meier plots of FFLR, FFDM and CSS in (A–C) all the patients; and (D–F) patients treated with gemcitabine-based chemoradiotherapy, grouped by ribonucleoside reductase subunit M1 status. FFLR, freedom from local recurrence; FFDM, freedom from distant metastasis; CSS, cancer-specific survival.